174 related articles for article (PubMed ID: 32341684)
21. Application of benchmark analysis for mixed contaminant exposures: Mutual adjustment of perfluoroalkylate substances associated with immunotoxicity.
Budtz-Jørgensen E; Grandjean P
PLoS One; 2018; 13(10):e0205388. PubMed ID: 30339706
[TBL] [Abstract][Full Text] [Related]
22. Update: use of the benchmark dose approach in risk assessment.
; Hardy A; Benford D; Halldorsson T; Jeger MJ; Knutsen KH; More S; Mortensen A; Naegeli H; Noteborn H; Ockleford C; Ricci A; Rychen G; Silano V; Solecki R; Turck D; Aerts M; Bodin L; Davis A; Edler L; Gundert-Remy U; Sand S; Slob W; Bottex B; Abrahantes JC; Marques DC; Kass G; Schlatter JR
EFSA J; 2017 Jan; 15(1):e04658. PubMed ID: 32625254
[TBL] [Abstract][Full Text] [Related]
23. Guidance on the use of the benchmark dose approach in risk assessment.
; More SJ; Bampidis V; Benford D; Bragard C; Halldorsson TI; Hernández-Jerez AF; Bennekou SH; Koutsoumanis K; Lambré C; Machera K; Mennes W; Mullins E; Nielsen SS; Schrenk D; Turck D; Younes M; Aerts M; Edler L; Sand S; Wright M; Binaglia M; Bottex B; Abrahantes JC; Schlatter J
EFSA J; 2022 Oct; 20(10):e07584. PubMed ID: 36304832
[TBL] [Abstract][Full Text] [Related]
24. Estimates of cancer potency of 2,3,7,8-tetrachlorodibenzo(p)dioxin using linear and nonlinear dose-response modeling and toxicokinetics.
Simon T; Aylward LL; Kirman CR; Rowlands JC; Budinsky RA
Toxicol Sci; 2009 Dec; 112(2):490-506. PubMed ID: 19776211
[TBL] [Abstract][Full Text] [Related]
25. Benchmark dose modeling for epidemiological dose-response assessment using prospective cohort studies.
De Pretis F; Zhou Y; Xun P; Shao K
Risk Anal; 2024 Apr; 44(4):743-756. PubMed ID: 37496455
[TBL] [Abstract][Full Text] [Related]
26. Quantitative Integration of Mode of Action Information in Dose-Response Modeling and POD Estimation for Nonmutagenic Carcinogens: A Case Study of TCDD.
Chen Q; Zhou Y; Ji C; Klaunig JE; Shao K
Environ Health Perspect; 2023 Dec; 131(12):127022. PubMed ID: 38157272
[TBL] [Abstract][Full Text] [Related]
27. Variation in benchmark dose (BMD) and the 95% lower confidence limit of benchmark dose (BMDL) among general Japanese populations with no anthropogenic exposure to cadmium.
Sakuragi S; Takahashi K; Hoshuyama T; Moriguchi J; Ohashi F; Fukui Y; Ikeda M
Int Arch Occup Environ Health; 2012 Nov; 85(8):941-50. PubMed ID: 22270387
[TBL] [Abstract][Full Text] [Related]
28. Benchmark dose risk analysis with mixed-factor quantal data in environmental risk assessment.
Sans-Fuentes MA; Piegorsch WW
Environmetrics; 2021 Aug; 32(5):. PubMed ID: 34354387
[TBL] [Abstract][Full Text] [Related]
29. Development of a benchmark dose for lead-exposure based on its induction of micronuclei, telomere length changes and hematological toxicity.
Wang T; Tu Y; Zhang G; Gong S; Wang K; Zhang Y; Meng Y; Wang T; Li A; Christiani DC; Au W; Zhu Y; Xia ZL
Environ Int; 2020 Dec; 145():106129. PubMed ID: 32950787
[TBL] [Abstract][Full Text] [Related]
30. Application of benchmark dose for occupational epidemiology in lead exposure.
Lin T; Xiao-Ting L; Ai G; Qiu-Ying L; Tai-Yi J
Toxicol Mech Methods; 2008; 18(4):363-7. PubMed ID: 20020903
[TBL] [Abstract][Full Text] [Related]
31. Development of a reference dose for BDE-47, 99, and 209 using benchmark dose methods.
Li LX; Chen L; Cao D; Chen BH; Zhao Y; Meng XZ; Xie CM; Zhang YH
Biomed Environ Sci; 2014 Sep; 27(9):733-9. PubMed ID: 25256863
[TBL] [Abstract][Full Text] [Related]
32. A benchmark dose analysis for sodium monofluoroacetate (1080) using dichotomous toxicity data.
Foronda NM; Fowles J; Smith N; Taylor M; Temple W
Regul Toxicol Pharmacol; 2007 Feb; 47(1):84-9. PubMed ID: 16965845
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the benchmark dose for point of departure determination for a variety of chemical classes in applied regulatory settings.
Izadi H; Grundy JE; Bose R
Risk Anal; 2012 May; 32(5):830-5. PubMed ID: 22126138
[TBL] [Abstract][Full Text] [Related]
34. Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?
Brandon EF; Bulder AS; van Engelen JG; Mahieu CM; Mennes WC; Pronk ME; Rietveld AG; van de Ven BM; Ten Voorde SE; Wolterink G; Slob W; Zeilmaker MJ; Bessems JG
Regul Toxicol Pharmacol; 2013 Nov; 67(2):182-8. PubMed ID: 23871753
[TBL] [Abstract][Full Text] [Related]
35. Considerations for application of benchmark dose modeling in radiation research: workshop highlights.
Chauhan V; Yu J; Vuong N; Haber LT; Williams A; Auerbach SS; Beaton D; Wang Y; Stainforth R; Wilkins RC; Azzam EI; Richardson RB; Khan MGM; Jadhav A; Burtt JJ; Leblanc J; Randhawa K; Tollefsen KE; Yauk CL
Int J Radiat Biol; 2023; 99(9):1320-1331. PubMed ID: 36881459
[TBL] [Abstract][Full Text] [Related]
36. Estimation of the benchmark dose of urinary cadmium as the reference level for renal dysfunction: a large sample study in five cadmium polluted areas in China.
Ke S; Cheng XY; Zhang JY; Jia WJ; Li H; Luo HF; Ge PH; Liu ZM; Wang HM; He JS; Chen ZN
BMC Public Health; 2015 Jul; 15():656. PubMed ID: 26169263
[TBL] [Abstract][Full Text] [Related]
37. Estimation of Benchmark Dose of Lifetime Cadmium Intake for Adverse Renal Effects Using Hybrid Approach in Inhabitants of an Environmentally Exposed River Basin in Japan.
Kubo K; Nogawa K; Kido T; Nishijo M; Nakagawa H; Suwazono Y
Risk Anal; 2017 Jan; 37(1):20-26. PubMed ID: 28076652
[TBL] [Abstract][Full Text] [Related]
38. Benchmark Dose Modeling of
Guo X; Mei N
Toxicol Res; 2018 Oct; 34(4):303-310. PubMed ID: 30370005
[TBL] [Abstract][Full Text] [Related]
39. Influence of Distribution of Animals between Dose Groups on Estimated Benchmark Dose and Animal Distress for Quantal Responses.
Kalantari F; Ringblom J; Sand S; Öberg M
Risk Anal; 2017 Sep; 37(9):1716-1728. PubMed ID: 28095605
[TBL] [Abstract][Full Text] [Related]
40. Properties of model-averaged BMDLs: a study of model averaging in dichotomous response risk estimation.
Wheeler MW; Bailer AJ
Risk Anal; 2007 Jun; 27(3):659-70. PubMed ID: 17640214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
